Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company. It develops innovative medicines for the treatment of serious and life-threatening diseases. The company's clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Its products also include HSP90 modulators, RTA 901, RORγt inhibitors, and RTA 1701. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), alport syndrome and other kidney diseases; and omaveloxolone in Friedreich’s ataxia. The company works in partnership with academics, biotechnology, and pharmaceutical companies to develop technologies. It operates in the US, the UK, Ireland, Australia and Switzerland. Reata is headquartered in Plano, Texas, the US.
Headquarters
United States of America
Address
5320 Legacy Dr, Plano, Texas, 75024-3127
Website
www.reatapharma.com
Telephone
1 972 8652219
No of Employees
321
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$2.2M
Reata Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Bardoxolone Methyl and Omaveloxolone |
| RTA 1701 |
| RTA 901 |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In July, the company received a takeover offer from Biogen. |
| 2023 | Regulatory Approval | In June, the company announced that the United States Food and Drug Administration (FDA) approved the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS. |
| 2023 | Regulatory Approval | In February, the company announced that the U.S. Food and Drug Administration approved SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents. |
Competitor Comparison
| Key Parameters | Reata Pharmaceuticals Inc | Bayer AG | Sanofi | AstraZeneca Plc | Eli Lilly and Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | France | United Kingdom | United States of America |
| City | Plano | Leverkusen | Paris | Cambridge | Indianapolis |
| State/Province | Texas | Nordrhein-Westfalen | Ile-de-France | England | Indiana |
| No. of Employees | 321 | 99,723 | 87,994 | 89,900 | 43,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| J. Warren Huff | Secretary; Chief Executive Officer; Chairman | Executive Board | 2002 | 69 |
| Manmeet S. Soni | Chief Operating Officer; Chief Financial Officer; President | Senior Management | 2022 | 45 |
| Bhaskar Anand | Senior Vice President; Chief Accounting Officer | Senior Management | - | - |
| Michael D. Wortley | Executive Vice President; Chief Legal Officer; Chief Compliance Officer | Senior Management | 2015 | 75 |
| Samina Khan | Chief Medical Officer; Senior Vice President | Senior Management | 2020 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward